Get the Stockscreener App
3.21
3.89%
-0.13
After Hours:
3.19
-0.02
-0.62%
Larimar Therapeutics Inc stock is traded at $3.21, with a volume of 446.40K.
It is down -3.89% in the last 24 hours and down -1.23% over the past month.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
See More
Previous Close:
$3.34
Open:
$3.36
24h Volume:
446.40K
Relative Volume:
0.36
Market Cap:
$266.72M
Revenue:
-
Net Income/Loss:
$-36.95M
P/E Ratio:
-3.8214
EPS:
-0.84
Net Cash Flow:
$-33.46M
1W Performance:
+4.56%
1M Performance:
-1.23%
6M Performance:
-13.24%
1Y Performance:
-0.62%
1-Day Range:
$3.18
$3.40
1-Week Range:
$3.11
$3.48
52-Week Range:
$1.61
$5.37
Larimar Therapeutics Inc Stock (LRMR) Company Profile
Name
Larimar Therapeutics Inc
Sector
Industry
Phone
844-511-9056
Address
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.21 | 277.52M | 0 | -36.95M | -33.46M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Initiated | Truist | Buy |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Oct-03-24 | Initiated | Wedbush | Outperform |
| Oct-02-24 | Initiated | H.C. Wainwright | Buy |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Apr-03-24 | Initiated | Leerink Partners | Outperform |
| Nov-17-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-19-22 | Initiated | Guggenheim | Buy |
| Feb-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-10-21 | Initiated | JMP Securities | Mkt Outperform |
| Feb-01-21 | Initiated | William Blair | Outperform |
View All
Larimar Therapeutics Inc Stock (LRMR) Latest News
Gap Down: Will Larimar Therapeutics Inc benefit from geopolitical trendsJuly 2025 Drop Watch & Consistent Return Strategy Ideas - baoquankhu1.vn
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Guidance Update: Does Larimar Therapeutics Inc have consistent dividend growthJuly 2025 Setups & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Geopolitics Watch: Is Larimar Therapeutics Inc. being accumulated by smart money2025 Price Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Portfolio Update: Is Smith Douglas Homes Corp a cyclical or defensive stockQuarterly Risk Review & Verified Short-Term Trading Plans - baoquankhu1.vn
Larimar Therapeutics executes strategic stock exchange agreement - MSN
Larimar’s Pediatric Friedreich’s Ataxia Trial Termination: What Investors Should Know - TipRanks
Friedreich's Ataxia Pipeline 2025: FDA Approvals and Clinical - openPR.com
AIGH Capital Management LLC Takes $3.23 Million Position in Larimar Therapeutics, Inc. $LRMR - MarketBeat
We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully - Sahm
Head-To-Head Survey: Oncology Pharma (OTCMKTS:ONPH) vs. Larimar Therapeutics (NASDAQ:LRMR) - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care (NASDAQ:LRMR) - Seeking Alpha
Aug Gainers: What risks investors should watch in Larimar Therapeutics Inc stockQuarterly Profit Summary & Low Risk Entry Point Guides - Bộ Nội Vụ
Published on: 2026-01-14 08:49:57 - Bộ Nội Vụ
Death Cross: How Larimar Therapeutics Inc stock performs during Fed tightening cyclesM&A Rumor & Risk Adjusted Buy and Sell Alerts - Bộ Nội Vụ
Published on: 2026-01-13 20:02:33 - Bộ Nội Vụ
Aug Intraday: Will Larimar Therapeutics Inc. stock outperform value stocks2025 Technical Patterns & Risk Adjusted Buy/Sell Alerts - Bộ Nội Vụ
Published on: 2026-01-13 12:38:02 - moha.gov.vn
Volatility Watch: Does Larimar Therapeutics Inc have a sustainable dividendTrade Risk Assessment & AI Forecast Swing Trade Picks - baoquankhu1.vn
Will Larimar Therapeutics Inc. stock outperform value stocksTrade Volume Summary & Pattern Based Trade Signal System - ulpravda.ru
Contact | Statesman-ExaminerLarimar Therapeutics, Inc.Common Stock (Nasdaq:LRMR) Detailed Stock Data - FinancialContent
Why Larimar Therapeutics Inc. stock remains resilientRate Cut & AI Powered Market Entry Strategies - Улправда
Larimar Therapeutics Advances Friedreich’s Ataxia Program with New Publications on Nomlabofusp Data - MSN
How Larimar Therapeutics Inc. (ZA71) stock trades after rate cutsMarket Volume Report & Low Risk Entry Point Tips - ulpravda.ru
Will Larimar Therapeutics Inc. (ZA71) stock see valuation expansionWeekly Gains Summary & Weekly Watchlist for Hot Stocks - Улправда
Why Larimar Therapeutics Inc. (ZA71) stock could outperform next yearPortfolio Value Report & Risk Adjusted Buy and Sell Alerts - Улправда
How Larimar Therapeutics Inc. (ZA71) stock correlates with oil marketsRisk Mitigation Techniques & Affordable Market Strategies - ulpravda.ru
Larimar Therapeutics (NASDAQ:LRMR) Raised to "Strong-Buy" at Leerink Partnrs - MarketBeat
How buybacks impact Larimar Therapeutics Inc. stock value2026 world cup usa national team third place match young talents high defensive line group prediction breakdown - Улправда
Leerink Partners assumes coverage on Larimar Therapeutics stock with Outperform rating - Investing.com Canada
Short Interest in Larimar Therapeutics, Inc. (NASDAQ:LRMR) Decreases By 19.2% - MarketBeat
Why Larimar Therapeutics Inc. stock could rally in 2025Quarterly Portfolio Summary & Safe Entry Trade Reports - moha.gov.vn
Comparing Altimmune (NASDAQ:ALT) & Larimar Therapeutics (NASDAQ:LRMR) - Defense World
Larimar heads to JPMorgan as rare disease program draws investor attention - MSN
Larimar Heads to JPMorgan as Rare Disease Program Draws Investor Attention - MyChesCo
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Should I hold or sell Larimar Therapeutics Inc. stock in 20252025 Sector Review & Smart Money Movement Tracker - Улправда
How institutional buying supports Larimar Therapeutics Inc. stockJuly 2025 Update & Reliable Intraday Trade Plans - Улправда
Is Larimar Therapeutics Inc. stock a contrarian buyInsider Buying & Daily Technical Stock Forecast Reports - Улправда
Moving Averages: Can Larimar Therapeutics Inc. stock rebound after recent weakness2025 Earnings Surprises & Accurate Technical Buy Alerts - Улправда
Market Fear: How Larimar Therapeutics Inc. (ZA71) stock correlates with oil marketsJuly 2025 Outlook & Precise Swing Trade Entry Alerts - Улправда
Published on: 2025-12-20 00:54:00 - Улправда
Why Larimar Therapeutics Inc. stock appeals to analysts2025 Stock Rankings & Risk Controlled Stock Alerts - bolumsonucanavari.com
Published on: 2025-12-19 13:18:47 - ulpravda.ru
Published on: 2025-12-19 05:26:13 - Улправда
Is Larimar Therapeutics Inc. (ZA71) stock a buy during volatile marketsPrice Action & Comprehensive Market Scan Insights - Улправда
Why Larimar Therapeutics Inc. stock remains on buy lists2025 Sector Review & Risk Managed Investment Strategies - Улправда
Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Why Larimar Therapeutics Inc. stock is recommended by analystsPortfolio Gains Summary & AI Based Buy/Sell Signal Reports - Улправда
Larimar Therapeutics Inc Stock (LRMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):